Eisai has been given a grant from the UK government that will be used to expand a facility in Hatfield, Hertfordshire, which ...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their ...

The late-stage MonumenTAL-3 trial of Talvey (talquetamab), given in combination with J&J and Genmab's anti-CD38 antibody ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

Across the US, the UK, and parts of Europe, CGT progress is being held back by an inability to secure starting material ...

The results of the BRUIN CLL-322 trial, reported at the EHA congress, showed that adding the non-covalent BTK inhibitor to ...

As the World Health Organization reported in January 2026, those mental disorders range from mild to severe in terms of their impact on everyday life. Indeed, over 120,000 people die by suicide ...

Novo Nordisk has become the latest pharma group to be targeted by a cyberattack, with the company revealing that some patient ...

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

Takeda presented data across a range of therapeutics and indications at ASCO 2026, including on investigational drugs like ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor – was more effective than Sotyktu ...